New Alzheimer’s Treatment Shows Real Promise in Slowing Cognition Decline Using Antibody in Human Trials
The major pharmaceutical company Eli Lilly has just demonstrated efficacy of their Alzheimer’s drug donanemab in phase 2 clinical human trials. The results are a major development for the treatment of a disease that currently affects six